John Joseph Wright

478 total citations
31 papers, 312 citations indexed

About

John Joseph Wright is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, John Joseph Wright has authored 31 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in John Joseph Wright's work include Renal cell carcinoma treatment (8 papers), Prostate Cancer Treatment and Research (7 papers) and Cancer Treatment and Pharmacology (5 papers). John Joseph Wright is often cited by papers focused on Renal cell carcinoma treatment (8 papers), Prostate Cancer Treatment and Research (7 papers) and Cancer Treatment and Pharmacology (5 papers). John Joseph Wright collaborates with scholars based in United States, Canada and South Korea. John Joseph Wright's co-authors include Matthew J. Walters, Yu Wang, Zheng Wei, Juan C. Jaén, Daniel J. Dairaghi, Pirow Bekker, Emily Wendt, Andrew M. K. Pennell, Mark E.T. Penfold and Trageen Baumgart and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Pharmacology and Experimental Therapeutics and Bioorganic & Medicinal Chemistry Letters.

In The Last Decade

John Joseph Wright

31 papers receiving 305 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Joseph Wright United States	8	141	89	81	80	72	31	312
Haruhito Sakata Japan	13	154 1.1×	62 0.7×	84 1.0×	81 1.0×	251 3.5×	34	483
Marie-Léa Gauci France	8	257 1.8×	88 1.0×	57 0.7×	44 0.6×	47 0.7×	12	342
Aiwen Wu China	11	283 2.0×	99 1.1×	124 1.5×	69 0.9×	98 1.4×	29	429
Mauro Alessandro Scotti Italy	9	205 1.5×	32 0.4×	76 0.9×	126 1.6×	113 1.6×	29	444
Liisa Chang United Kingdom	4	183 1.3×	49 0.6×	107 1.3×	46 0.6×	100 1.4×	5	332
Claus von Weyhern Germany	9	158 1.1×	34 0.4×	192 2.4×	224 2.8×	107 1.5×	14	429
Shinya Ohara Japan	12	159 1.1×	32 0.4×	152 1.9×	135 1.7×	115 1.6×	29	376
M.T. Allende Spain	12	127 0.9×	22 0.2×	109 1.3×	74 0.9×	132 1.8×	32	363
Deyu Zhang China	12	90 0.6×	34 0.4×	131 1.6×	64 0.8×	164 2.3×	34	424
Marion Jacquin France	8	161 1.1×	128 1.4×	56 0.7×	37 0.5×	156 2.2×	16	340

Countries citing papers authored by John Joseph Wright

Since Specialization

Citations

This map shows the geographic impact of John Joseph Wright's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Joseph Wright with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Joseph Wright more than expected).

Fields of papers citing papers by John Joseph Wright

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Joseph Wright. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Joseph Wright. The network helps show where John Joseph Wright may publish in the future.

Co-authorship network of co-authors of John Joseph Wright

This figure shows the co-authorship network connecting the top 25 collaborators of John Joseph Wright. A scholar is included among the top collaborators of John Joseph Wright based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Joseph Wright. John Joseph Wright is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Coyne, Geraldine O’Sullivan, Larry Rubinstein, Naoko Takebe, et al.. (2024). Pilot study of CBX-12 pharmacodynamics in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3187–TPS3187. 1 indexed citations

Heumann, Thatcher, Mark Yarchoan, Hao Wang, et al.. (2023). ETCTN 10476: A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.. Journal of Clinical Oncology. 41(4_suppl). TPS639–TPS639. 3 indexed citations

Damodaran, Senthil, Fengmin Zhao, Dustin A. Deming, et al.. (2020). Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.. Journal of Clinical Oncology. 38(15_suppl). 3506–3506. 3 indexed citations

Gounder, Mrinal M., Michelle R. Mahoney, Brian Andrew Van Tine, et al.. (2018). Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).. Journal of Clinical Oncology. 36(15_suppl). 11500–11500. 6 indexed citations

Apolo, Andrea B., Amir Mortazavi, Mark N. Stein, et al.. (2017). A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.. Journal of Clinical Oncology. 35(6_suppl). 293–293. 36 indexed citations

Dhani, Neesha C., Qian Tan, Angela Jain, et al.. (2017). Exploratory phase II evaluation of cabozantinib in recurrent/metastatic uterine carcinosarcoma (CS): A study of the Princess Margaret, Chicago, and California phase II consortia.. Journal of Clinical Oncology. 35(15_suppl). 5587–5587. 1 indexed citations

Pal, Sumanta K., Catherine M. Tangen, Ian M. Thompson, et al.. (2017). A randomized, phase II efficacy assessment of multiple MET kinase inhibitors in metastatic papillary renal carcinoma (PRCC): SWOG S1500.. Journal of Clinical Oncology. 35(15_suppl). TPS4599–TPS4599. 7 indexed citations

Dhani, Neesha C., Hal W. Hirte, Marcus O. Butler, et al.. (2016). Phase II study of cabozantinib in recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago and California Phase II Consortia.. Journal of Clinical Oncology. 34(15_suppl). 5586–5586. 1 indexed citations

Srivastava, Apurva K., Jeevan Prasaad Govindharajulu, Sook Ryun Park, et al.. (2016). Pazopanib to suppress MET signaling in patients with refractory advanced solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 2553–2553. 4 indexed citations

10.

Monk, Paul, Glenn Liu, Walter M. Stadler, et al.. (2015). Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 33(7_suppl). 146–146. 7 indexed citations

11.

Karzai, Fatima, Ravi A. Madan, Marc R. Theoret, et al.. (2015). Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 33(7_suppl). 235–235. 2 indexed citations

12.

Tolaney, Sara M., Hao Guo, William T. Barry, et al.. (2014). A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer.. Journal of Clinical Oncology. 32(15_suppl). 1106–1106. 3 indexed citations

13.

Chuk, Meredith K., Brigitte C. Widemann, Charlotte H. Ahern, et al.. (2014). A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children’s Oncology Group phase I consortium trial.. Journal of Clinical Oncology. 32(15_suppl). 10078–10078. 6 indexed citations

14.

El-Khoueiry, Anthony B., Robert T. OʼDonnell, Philip C. Mack, et al.. (2014). A phase I trial of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 32(3_suppl). 293–293. 1 indexed citations

15.

Pennell, Andrew M. K., James B. Aggen, Subhabrata Sen, et al.. (2013). 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists. Bioorganic & Medicinal Chemistry Letters. 23(5). 1228–1231. 11 indexed citations

16.

Apolo, Andrea B., Howard L. Parnes, Ravi A. Madan, et al.. (2013). A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma.. Journal of Clinical Oncology. 31(15_suppl). TPS4589–TPS4589. 7 indexed citations

17.

Srivastava, Apurva K., Melinda G. Hollingshead, Jennifer Weiner, et al.. (2013). Application of MET pharmacodynamic assays to compare effectiveness of five MET inhibitors to engage target in tumor tissue.. Journal of Clinical Oncology. 31(15_suppl). 11103–11103. 1 indexed citations

18.

Adesunloye, Bamidele, Xuan Huang, Yang‐Min Ning, et al.. (2012). Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 30(15_suppl). 4569–4569. 6 indexed citations

19.

Mehnert, Janice M., Antoinette R. Tan, Rebecca A. Moss, et al.. (2012). A phase I trial of riluzole and sorafenib in patients with advanced solid tumors and melanoma.. Journal of Clinical Oncology. 30(15_suppl). TPS3112–TPS3112. 3 indexed citations

20.

Walters, Matthew J., Yu Wang, Trageen Baumgart, et al.. (2010). Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease. Journal of Pharmacology and Experimental Therapeutics. 335(1). 61–69. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact